Biotechnology exchange traded funds can hold a hodgepodge of businesses with approved drugs and those focused on clinical trials. So ETF sponsor BioShares puts these companies into two distinct funds. Biotechnology Clinical Trials (BBC) and Biotechnology Products (BBP) launched in December 2014. The ETFs started with a little over $5 million combined. They now together hold roughly $58 million. They're also outperforming bigger, more established <>
Thursday 16 July 2015
Manager Of Hot New Biotech ETFs Explains The Strategy
Otmane El Rhazi from Investor's Business Daily - ETFs RSS.
Biotechnology exchange traded funds can hold a hodgepodge of businesses with approved drugs and those focused on clinical trials. So ETF sponsor BioShares puts these companies into two distinct funds. Biotechnology Clinical Trials (BBC) and Biotechnology Products (BBP) launched in December 2014. The ETFs started with a little over $5 million combined. They now together hold roughly $58 million. They're also outperforming bigger, more established <>
Biotechnology exchange traded funds can hold a hodgepodge of businesses with approved drugs and those focused on clinical trials. So ETF sponsor BioShares puts these companies into two distinct funds. Biotechnology Clinical Trials (BBC) and Biotechnology Products (BBP) launched in December 2014. The ETFs started with a little over $5 million combined. They now together hold roughly $58 million. They're also outperforming bigger, more established <>
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment